DrugPatentWatch Database Preview
NASONEX Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Nasonex, and when can generic versions of Nasonex launch?
This drug has forty-six patent family members in thirty-three countries.
The generic ingredient in NASONEX is mometasone furoate. There are twenty-nine drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Summary for NASONEX
| International Patents: | 46 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 4 |
| Bulk Api Vendors: | 57 |
| Clinical Trials: | 44 |
| Patent Applications: | 4,130 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NASONEX |
| DailyMed Link: | NASONEX at DailyMed |
Pharmacology for NASONEX
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for NASONEX
Synonyms for NASONEX
| (11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
| (11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione |
| (1R,2S,10S,11S,13R,14R,15S,17S)-1-CHLORO-14-(2-CHLOROACETYL)-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE |
| (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate |
| (9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
| [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
| [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
| 04201GDN4R |
| 11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate |
| 2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester |
| 83919-23-7 |
| 9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
| 9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) |
| 919M237 |
| A840685 |
| AB2000407 |
| AC-941 |
| AC1L9AZS |
| AK163902 |
| AKOS015994732 |
| AN-15438 |
| Asmanex |
| Asmanex HFA |
| Asmanex Twisthaler |
| BC228151 |
| BDBM50148733 |
| BPBio1_000424 |
| BRD-K60640630-001-03-7 |
| BRN 4340538 |
| BSPBio_000384 |
| C07817 |
| C27H30Cl2O6 |
| CAS-83919-23-7 |
| CCG-220572 |
| CHEBI:47564 |
| CHEMBL1161 |
| CS-2389 |
| D00690 |
| Danitin |
| DR003147 |
| DSSTox_CID_3333 |
| DSSTox_GSID_23333 |
| DSSTox_RID_76981 |
| DTXSID4023333 |
| Ecural |
| Elocon |
| Elocone |
| Elomet |
| Flumeta |
| HMS1569D06 |
| HMS2096D06 |
| HMS2235I14 |
| HY-13693 |
| KS-00000SPL |
| KS-1275 |
| LAS 41002 |
| M2354 |
| MLS002153879 |
| MolPort-003-849-257 |
| Mometasone 17-(2-furoate) |
| mometasone 17-furoate |
| mometasone furancarboxylate |
| mometasone furoate |
| Mometasone furoate (JAN/USP) |
| Mometasone furoate [USAN:USP:JAN] |
| Mometasone furoate hydrate |
| Mometasone Furoate Impurity G |
| MOMETASONE FUROATE MONOHYDRATE |
| Mometasone furoate, >=98% (HPLC) |
| Mometasone furoate, European Pharmacopoeia (EP) Reference Standard |
| Mometasone Furoate, pharmaceutical secondary standard; traceable to USP, PhEur and BP |
| Mometasone furoate, United States Pharmacopeia (USP) Reference Standard |
| Monovo |
| NCGC00016950-01 |
| NCGC00179578-01 |
| NCGC00179578-03 |
| NCGC00179578-04 |
| Nosorex |
| NSC-746171 |
| NSC746171 |
| Ovixan |
| PL071566 |
| Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- |
| Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)- |
| Prestwick_924 |
| Prestwick0_000572 |
| Prestwick1_000572 |
| Prestwick2_000572 |
| Prestwick3_000572 |
| Q-101380 |
| Rimelon |
| s1987 |
| Sch 32088 |
| Sch-32088 |
| SCHEMBL4568 |
| Sinuva |
| SMR001233233 |
| SPBio_002603 |
| SR-01000841209 |
| SR-01000841209-2 |
| ST24048112 |
| TL8005500 |
| Tox21_110705 |
| Tox21_110705_1 |
| UNII-04201GDN4R |
| WOFMFGQZHJDGCX-ZULDAHANSA-N |
| ZINC3938677 |
US Patents and Regulatory Information for NASONEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for NASONEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Sign Up | ➤ Sign Up |
| Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Sign Up | ➤ Sign Up |
| Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Sign Up | ➤ Sign Up |
| Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for NASONEX
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 50 mcg/ Spray | ➤ Subscribe | 2009-08-07 |
Non-Orange Book US Patents for NASONEX
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,180,781 | Process for making mometasone furoate monohydrate | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for NASONEX
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Yugoslavia | 48666 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 9204365 | ➤ Sign Up |
| Taiwan | 229208 | ➤ Sign Up |
| European Patent Office | 0548114 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for NASONEX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB97/064 | United Kingdom | ➤ Sign Up | PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410 |
| C0002 | Belgium | ➤ Sign Up | PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622 |
| 875032 | Germany | ➤ Sign Up | PRODUCT NAME: MOMETASON-FUROAT-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 40803.00.00 19980218; FIRST REGISTRATION: FRANKREICH NL 22055 19970219 |
| 0012 | Netherlands | ➤ Sign Up | 980012, 20110905, EXPIRES: 20160905 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
